ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...
Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ®) platform to develop a new class of genetic medicines for rare ...
The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains ...
RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results